Electronics

January 13, 2026, 7:08 AM EST. Eli Lilly and Nvidia announced a five-year plan to invest up to $1 billion to create an AI-powered laboratory in the San Francisco Bay Area to accelerate drug discovery and development. The facility will rely on Nvidia's BioNeMo platform and Vera Rubin computing architecture, and will deploy robotics and physical AI tools to move candidates from research to production. Nvidia CEO Jensen Huang said AI is reshaping every industry, with life sciences among the most promising areas. Lilly CEO David Ricks said the partnership could unlock breakthroughs by combining Lilly's data and scientific expertise with Nvidia's computing power. The deal reflects a broader trend of big pharma teaming with AI leaders to shorten timelines and boost research efficiency.